Alabama Medical Cannabis Sales Gear for Spring 2026 Launch

Alabama’s medical cannabis program is preparing for retail sales to begin in spring 2026, establishing a new market clinicians must understand for patient recommendations and treatment protocols.

Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds

Cannabis cannabinoids CBD and CBG show potential therapeutic effects against hepatic steatosis, providing clinicians with evidence-based compounds to consider for patients with fatty liver disease management.

From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …

The article examines regulatory enforcement actions against cannabis beverage products, highlighting compliance challenges clinicians should understand when advising patients on legal product availability and safety standards.

Cannabis Compounds CBD and CBG Show Promise in Reducing Liver Fat and Improving …

CBD and CBG cannabinoids demonstrate potential therapeutic effects on hepatic steatosis and metabolic markers, offering clinicians evidence-based compounds for managing cannabis-associated liver health concerns in patients.

New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …

I’m unable to complete this task because the article summary is missing. Please provide the summary text so I can write an accurate one-sentence description for cannabis clinicians.

New Top Cannabis Regulator Sets Priorities In First Board Meeting

A newly appointed cannabis regulator outlined initial priorities at their first board meeting, affecting clinical cannabis practice standards and regulatory compliance requirements.

Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead

Brazil’s evolving cannabis regulations, their clinical implications, and implementation challenges for healthcare providers operating within the country’s legal framework.

2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT

Two Cincinnati breweries are challenging Ohio’s prohibition on THC-infused beverages through litigation, establishing legal precedent relevant to cannabis product regulation and clinical cannabinoid delivery methods.

New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVG

Ohio’s new law restricts retail distribution of THC-infused beverages, affecting patient access to alternative consumption methods and requiring clinicians to adjust counseling on available product options.

Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – Yahoo

Oregon lawmakers rejected legislation that would have limited THC concentrations in cannabis edibles, maintaining current regulatory flexibility for product formulation and potency standards.

Attempt to limit potency of THC in marijuana edibles fails at Oregon Legislature

Oregon legislators failed to pass restrictions on THC potency in cannabis edibles, potentially affecting dosing standardization and patient safety management for clinical practitioners.

Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic Health

Cannabis compounds CBD and CBG reduce hepatic steatosis and improve metabolic markers, offering potential therapeutic applications for non-alcoholic fatty liver disease management in clinical cannabis practice.

Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed

This article examines formulation and fabrication techniques for delivering cannabinoids through oral mucosal tissues, which is clinically relevant for developing alternative administration routes with potentially improved bioavailability and patient outcomes.

Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML

CBD-dominant cannabis products demonstrated significant anxiety relief in research, providing clinicians with evidence-based information for patient treatment recommendations.

Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML

This article reports clinical trial results showing cannabis extracts’ efficacy in reducing myofascial pain, providing evidence-based data relevant to clinicians treating musculoskeletal pain conditions.

As a Medical Cannabis Patient, I’m Watching This Supreme Court Case Closely

This article discusses a Supreme Court case relevant to medical cannabis patients and its potential implications for cannabis clinical practice and patient access.

The Week in Weed: March 2026 | Seyfarth Shaw LLP – JDSupra

Please share the article content, and I’ll provide a concise, factual summary within 40 words.

Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus Dispatch

Marijuana gummies sold in Ohio are being recalled, requiring clinicians to be aware of potential patient safety issues and advise patients to verify product authenticity and safety status.

New Group Launches Ahead of Medicare CBD Pilots – Cannabis Wire

A new organization is forming to prepare for upcoming Medicare-sponsored CBD clinical pilot programs, establishing infrastructure for evidence-based cannabidiol research within the federal healthcare system.

Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PA

This resource covers legal classifications and regulatory statuses of marijuana, which directly impacts a clinician’s prescribing authority, liability exposure, and documentation requirements across jurisdictions.

Louisiana lawmaker files bill to legalize recreational marijuana through licensed dispensaries

A Louisiana legislator proposed legalizing recreational marijuana sales through regulated dispensaries, which could expand patient access and create standardized product oversight relevant to clinical practice.

Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries

A Georgia mother’s homemade medical cannabis formulation has entered commercial dispensary distribution, demonstrating consumer-developed cannabis preparations entering regulated medical markets.

Ohio THC drink ban draws lawsuit from Cincinnati breweries

Ohio’s THC beverage restriction prompts legal challenges from breweries, affecting regulatory frameworks that cannabis clinicians must monitor for patient access and product availability changes.

Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease

Israeli researchers identified cannabis compounds as potential therapeutic agents for fatty liver disease, representing the first pharmacological option for this currently untreatable condition affecting millions globally.

Virginia adult-use sales bills pass both chambers, head to conference committee! – Blog

Virginia’s adult-use cannabis sales bills passed both legislative chambers and now require reconciliation, potentially establishing legal retail sales that could affect patient access pathways and clinical recommendations.

Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown

A study examining medical marijuana’s benefits and drawbacks informs clinical practice considerations while Tennessee’s regulatory status remains uncertain for healthcare providers.

2026 Utah legislature on cannabis, psychedelics and kratom – Fox 13

The 2026 Utah legislature addresses regulatory and legal frameworks for cannabis, psychedelics, and kratom, directly impacting clinical prescribing practices and patient access in Utah.

Oregon Bill To Ban Marijuana Edibles With More Than 10 Milligrams Of THC Fails

Oregon legislators rejected a proposal to limit THC content in cannabis edibles to 10mg per unit, affecting product standardization and dosing guidance for clinical practitioners.

Georgia bill could limit probable cause for smell of marijuana, cannabis, or hemp – YouTube

Georgia legislation would restrict law enforcement’s ability to use marijuana/hemp odor alone as probable cause for searches, affecting how clinicians document patient use and legal compliance documentation.

Study reveals cannabis compounds reduce threat of fatty liver disease | Health

Cannabis compounds show potential therapeutic application for fatty liver disease management, providing clinicians with emerging evidence to evaluate when counseling patients on cannabinoid-based treatment options.

The digest reflects a significant shift in cannabis research toward specific therapeutic applications, with emerging evidence supporting cannabinoid-based interventions for metabolic and pain-related conditions that currently have limited treatment options. Regulatory frameworks are evolving unevenly across jurisdictions, creating inconsistent approaches to product formulation standards and market access that complicate clinical implementation and patient safety considerations. These developments suggest the field is transitioning from broad cannabis legalization toward more targeted investigation of individual cannabinoid compounds and their clinical efficacy, though regulatory standardization remains a substantial gap between promising research findings and clinical practice.

FAQ

This News item was assembled from structured source metadata and pipeline scoring.